News und Analysen
![EOS Imaging Reports Strong Revenue Growth for Half Year 2020](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EOS Imaging Reports Strong Revenue Growth for Half Year 2020
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
![Evotec: Innovative Krebsforschungs-Partnerschaft!](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Evotec: Innovative Krebsforschungs-Partnerschaft!
Evotec (WKN: 566480) gibt heute eine Partnerschaft mit dem Wiener Universitäts-Spinoff Quantro Therapeutics bekannt, an dem sich das Hamburger Biotechunternehmen zudem Anteile sichert.
Der
![Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE) today announced initial data from their ongoing German Phase 1/2, open-label, non-randomized
![Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE) today announced initial data from their ongoing German Phase 1/2, open-label, non-randomized
![Heat Biologics: Erste NBC-Empfehlung mit +1.375% in 5 Monaten](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Heat Biologics: Erste NBC-Empfehlung mit +1.375% in 5 Monaten
Mit Heat Biologics (WKN: A2JB4Y) kannte die erste Empfehlung des weltweit einzigartig erfolgreichen No Brainer Clubs zuletzt kein Halten mehr. Seit Ende Februar steht eine Kursperformance von
![Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against
![Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against
![Quidel’s Sofia® SARS Antigen FIA Updates EUA Performance Data to 96.7% PPA Versus PCR; Product Supports U.S. Initiatives to Expand Access to COVID-19 Testing in Nursing Homes; Receives CE Mark for Use With Sofia® and Sofia® 2 Instruments](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Quidel’s Sofia® SARS Antigen FIA Updates EUA Performance Data to 96.7% PPA Versus PCR; Product Supports U.S. Initiatives to Expand Access to COVID-19 Testing in Nursing Homes; Receives CE Mark for Use With Sofia® and Sofia® 2 Instruments
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of
![LivaNova kündigt die kommerzielle Markteinführung der Aorten-Herzklappe Perceval Plus in Europa an](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
LivaNova kündigt die kommerzielle Markteinführung der Aorten-Herzklappe Perceval Plus in Europa an
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Medizintechnik- und Innovationsunternehmen, gab heute bekannt, dass die fortschrittliche nahtlos-chirurgische Aorten-Herzklappe Perceval® Plus jetzt
![Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX®
![Illumina to Announce Second Quarter 2020 Financial Results on Thursday, August 6, 2020](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina to Announce Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2020 following the close of market on Thursday, August 6, 2020.
On the same day, at 2:00 pm Pacific
![Illumina to Announce Second Quarter 2020 Financial Results on Thursday, August 6, 2020](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina to Announce Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2020 following the close of market on Thursday, August 6, 2020.
On the same day, at 2:00 pm Pacific
![Illumina to Announce Second Quarter 2020 Financial Results on Thursday, August 6, 2020](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Illumina to Announce Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2020 following the close of market on Thursday, August 6, 2020.
On the same day, at 2:00 pm Pacific
![Sartorius: Prognoseanhebung aufgrund der Covid-19-Pandemie](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sartorius: Prognoseanhebung aufgrund der Covid-19-Pandemie
Größter Gewinner in MDAX und TecDAX ist heute die Vorzugsaktie von Sartorius (WKN: 716563). Grund hierfür ist eine, bereits gestern Abend erfolgte, Prognoseanhebung.
Rechnete das Management um CEO
![Sartorius: Prognoseanhebung aufgrund der Covid-19-Pandemie](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Sartorius: Prognoseanhebung aufgrund der Covid-19-Pandemie
Größter Gewinner in MDAX und TecDAX ist heute die Vorzugsaktie von Sartorius (WKN: 716563). Grund hierfür ist eine, bereits gestern Abend erfolgte, Prognoseanhebung.
Rechnete das Management um CEO
![LivaNova Announces Commercial Launch of Perceval Plus Aortic Heart Valve in Europe](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
LivaNova Announces Commercial Launch of Perceval Plus Aortic Heart Valve in Europe
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced that the advanced Perceval® Plus sutureless surgical aortic heart valve is now available for
![Virginia Mason Health System Partners with Premier Inc. to Manage Supply Chain and Enhance Expense Management](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Virginia Mason Health System Partners with Premier Inc. to Manage Supply Chain and Enhance Expense Management
Virginia Mason Health System, a leading non-profit regional healthcare system serving the Pacific Northwest, and Premier Inc. (NASDAQ: PINC), a healthcare improvement company, have partnered to
![Waters Corporation Names Udit Batra President and Chief Executive Officer](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Waters Corporation Names Udit Batra President and Chief Executive Officer
Waters Corporation (NYSE:WAT) (“Waters” or the “Company”) today announced that Udit Batra, Ph.D. has been named the Company’s President and Chief Executive Officer, effective September 1, 2020. He
![Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating
![MorphoSys: Milliardendeals?!](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
MorphoSys: Milliardendeals?!
Bereits gestern Abend, nachbörslich, veröffentlichte das deutsche Biotechnologieunternehmen MorphoSys (WKN: 663200) eine bedeutende Ad hoc-Meldung. Die Aktie reagiert entsprechend.
Demnach hat der
![MorphoSys: Milliardendeals?!](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
MorphoSys: Milliardendeals?!
Bereits gestern Abend, nachbörslich, veröffentlichte das deutsche Biotechnologieunternehmen MorphoSys (WKN: 663200) eine bedeutende Ad hoc-Meldung. Die Aktie reagiert entsprechend.
Demnach hat der
![STAAR Surgical Company to Hold 2020 Annual Meeting of Shareholders in Virtual Format](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
STAAR Surgical Company to Hold 2020 Annual Meeting of Shareholders in Virtual Format
STAAR Surgical Company (NASDAQ: STAA) today announced that to support the health and well-being of its shareholders, employees, directors, and communities due to the public health threat of the
![Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report second fiscal quarter 2020
![Premier Inc. ProvideGx™ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Premier Inc. ProvideGx™ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care
Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize